A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
Inclusion Criteria:
Exclusion Criteria:
El Cajon, California 92020, United States
La Mesa, California 91942, United States
La Mesa, California 91942, United States
Lancaster, California 93534, United States
Lancaster, California 93534, United States
Los Angeles, California 90036, United States
Los Angeles, California 90067, United States
Brandon, Florida 33511, United States
Tampa, Florida 33603, United States
Hanover, Maryland 21076, United States
Harrisburg, Pennsylvania 17102, United States
Lemoyne, Pennsylvania 17043, United States
Houston, Texas 77030, United States
Houston, Texas 77030, United States
Houston, Texas 77030, United States
Tyler, Texas 75701, United States
Seattle, Washington 98104, United States
Birtinya, Queensland 4575, Australia
Grodno, 230023, Belarus
Sofia, 1606, Bulgaria
Olomouc, 779 00, Czechia
Ostrava-Poruba, 708 52, Czechia
Tbilisi, 0112, Georgia
Wroclaw, Lower Silesian Voivodeship 54-144, Poland
Szczecin, West Pomeranian Voivodeship 70-233, Poland
Lodz, 93-513, Poland
Nizhny Novgorod, 603126, Russia
Saint Petersburg, 191015, Russia
Saint Petersburg, 197022, Russia
Samara, 443001, Russia
Samara, 443011, Russia
Stavropol, 355017, Russia
Dnipro, 49005, Ukraine
Ivano-Frankivsk, 76008, Ukraine
Kharkiv, 61037, Ukraine
Kyiv, 02091, Ukraine
Vinnytsia, 21009, Ukraine
Vinnytsia, 21018, Ukraine
Vinnytsia, 21029, Ukraine